Intercontinental Exchange, Inc.’s (ICE - Free Report) average daily volume (ADV) in September decreased 10.7% to 6.1 million, largely attributable to lower Energy, Commodities and Financial ADV. There were 21 trading days in September.
Agriculture and Metals ADV of 0.4 million contracts declined 14.7%. Energy volume too decreased 10.6% to 2.8 million contracts per day. Thus, Commodities ADV decreased 11.2% to 3.3 million in September.
Interest rate volume dropped 12.2% to 2.1 million contracts per day whereas Equity Index volume declined 5% to 0.6 million contracts. Foreign exchange volume decreased 42.8% to nearly 0.05 million contracts.
Intercontinental Exchange’s third-quarter heating oil ADV increased 184% year over year, RBOB gasoline increased 261% year over year.
European natural gas ADV was up 5% year over year. North American natural gas ADV rose 9% year over year.
Shares of this Zacks Rank #3 (Hold) company have outperformed the industry in the past year. The stock has rallied 7.9% against the industry’s decline of 1.2%. The company’s compelling product portfolio, along with a broad range of risk management services, strategic buyouts and a robust capital position will likely help the stock bounce back.
September Volumes of Other Securities Exchanges
Recently, securities exchanges, namely CME Group Inc. (CME - Free Report) and MarketAxess Holdings Ltd. (MKTX - Free Report) and Cboe Global Markets, Inc. (CBOE - Free Report) also posted their respective September 2020 volumes.
While MarketAxess reported trading volume of $461.0 billion, consisting of $206.2 billion in credit volume and $254.8 billion in rates volume, Cboe Global posted ADV of 10.4 million contracts, up 26.4% year over year. CME Group reported ADV for September 2020 of 16.9 million contracts per day, down 14% year over year, attributable to lower volumes in four of the six product lines.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>